MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-12-2024
Psychemedics Corporation Market Cap 2011-2026 | PMD
As of April 09, 2026 Psychemedics Corporation has a market cap of $ 15.3 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Psychemedics Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.8 M | 29 M | 39 M | 28.1 M | 52.3 M | 102 M | 114 M | 140 M | 50.8 M | 80.1 M | 81.4 M | 62.8 M | 50.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 140 M | 16.8 M | 65.1 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
42 B | $ 116.92 | 2.67 % | $ 35.5 B |  USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
7.95 M | $ 1.18 | 0.85 % | $ 6.43 M | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 17.92 | 1.41 % | $ 955 M | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | - | - | $ 19.8 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 16.24 | 0.93 % | $ 175 M |  China |
 |
Co-Diagnostics
CODX
|
5.85 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
7.34 M | $ 1.98 | -0.63 % | $ 8.76 M | USA |
 |
Illumina
ILMN
|
16.4 B | $ 128.0 | 1.23 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 25.19 | 1.45 % | $ 700 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 274.72 | 2.06 % | $ 22.9 B | USA |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 175.07 | 3.26 % | $ 8.68 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 520.65 | 2.39 % | $ 15 B | USA |
 |
Danaher Corporation
DHR
|
150 B | $ 196.19 | 2.71 % | $ 140 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K |  Israel |
 |
Myriad Genetics
MYGN
|
409 M | $ 4.77 | 0.63 % | $ 442 M | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 10.34 | 3.61 % | $ 2.24 B | USA |
 |
National Research Corporation
NRC
|
315 M | $ 17.26 | 1.29 % | $ 386 M | USA |
 |
Natera
NTRA
|
5.31 B | $ 210.83 | 0.75 % | $ 20.7 B | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
3.1 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
9.12 M | - | -16.95 % | $ 1.54 M | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 15.83 | -0.5 % | $ 479 M | USA |
 |
Pacific Biosciences of California
PACB
|
498 M | $ 1.47 | 2.08 % | $ 441 M | USA |
 |
Guardant Health
GH
|
13.4 B | $ 92.84 | -0.49 % | $ 11.6 B | USA |
 |
PerkinElmer
PKI
|
14.1 B | - | -0.91 % | $ 14.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B |  Niderland |
 |
Personalis
PSNL
|
254 M | $ 6.33 | 2.59 % | $ 375 M | USA |
 |
Anixa Biosciences
ANIX
|
104 K | $ 2.73 | 1.49 % | $ 88.6 K | USA |
 |
Biomerica
BMRA
|
7.19 M | $ 2.15 | -0.46 % | $ 4.94 M | USA |
 |
Quotient Limited
QTNT
|
183 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 106.54 | -0.58 % | $ 8.79 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M | Israel |
 |
Celcuity
CELC
|
5.37 B | $ 116.94 | 1.19 % | $ 5.47 B | USA |